Ocean Biomedical, Inc. cash flow statement OCEA

In Q1 of fiscal 2025, the quarter ended Mar 31, 2025, Ocean Biomedical, Inc. used $356,000 of cash from operations, up 26.6% from the same quarter a year earlier.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Mar 31, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Q2 FY2024
Jun 30, 2024
Q1 FY2024
Mar 31, 2024
Q4 FY2023
Dec 31, 2023
Q3 FY2023
Sep 30, 2023
Q2 FY2023
Jun 30, 2023
Operating
Stock-based compensation
—
0
—
—
—
—
—
—
—
Operating cash flow
-4
+44.2%
-0
+26.6%
-2
-182.7%
-1
+15.3%
-0
+93.9%
-0
+81.7%
-1
-2524.2%
-1
-155.7%
-5
-3066.9%
Financing
Short-term debt issued
—
1
-36.2%
—
—
—
—
0
8
7
Short-term debt repaid
—
—
—
—
—
—
0
0
2
Financing cash flow
1
1
-68.9%
2
+189.9%
-9
-189.9%
—
—
1
+1812.2%
10
+5801.2%
7
+2502.7%
Change in cash
Net change in cash
0
+21.1%
1
+214.0%
-0
+40.7%
0
+101.0%
-0
-115.6%
-0
-278.3%
-0
+67.1%
-1
-303.6%
2
+1683.7%
Ratios
Cash conversion
—
—
—
—
—
-0.04x
—
—
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
OCEA (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1869974
Former names
Ocean Biomedical, Inc./DE (until Feb 15, 2023); Aesther Healthcare Acquisition Corp. (until Feb 14, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.